This report was prepared by members of the NHMRC Centre of Research Excellence in Cervical Cancer Control.
Julia Brotherton, Megan Smith, Lucy Boyd, Alvin Lee, Louise Mitchell, Amy Pagotto and Dorothy Machalek with contributions from Marion Saville, Deborah Bateson, Frank Beard, Telma Costa, David Hawkes, Monjura Nisha, Claire Vajdic, Lisa Whop, and Karen Canfell.
Brotherton J, Smith M, Boyd L, Lee A, Mitchell L, Pagotto A, Machalek D et al. 2026 Cervical Cancer Elimination Progress Report: Australia’s progress towards the elimination of cervical cancer as a public health problem. Published online 16/11/2026, Melbourne, Australia, at https://www.report.cervicalcancercontrol.org.au
For any enquiries about this report or the work of the CRE, please email us at c4.admin@sydney.edu.au
We are fortunate to work in a community with such skilled and generous colleagues to support timely sharing of information to support public health.
We would like to acknowledge the support of the Department of Health, Disability and Ageing, the work of the Screening Analysis and Monitoring Unit of the Australian Institute of Health and Welfare, in particular Alison Budd, the National Cancer Screening Register, and the work of the National Centre for Immunisation Research and Surveillance, particularly Alexandra Hendry, in preparing data for this report. We thank Mark Short and the team at the Australian Institute of Health and Welfare and the population-based cancer registries of New South Wales, Victoria, Queensland, Western Australia, South Australia, Tasmania, the Australian Capital Territory and the Northern Territory for the provision of data from the Australian Cancer Database. We also thank Reevanshi Sharma and Sharnel Perera for kindly providing data from the National Gynae-Oncology Registry. We also wish to thank Karen Zhao and Kerry Crooks from the data team at Australian Centre for the Prevention of Cervical Cancer for their assistance with preparing the report.
We hope these reports will help harness the political will, community support and our available resources to ensure elimination is achieved and that equity in outcomes for all remains front of mind. We look forward to a time in the near future when the report documents Australia’s achievement of the elimination of cervical cancer as a public health problem.
ABS: Australian Bureau of Statistics
AIHW: Australian Institute of Health and Welfare
AIR: Australian Immunisation Register
AIS: adenocarcinoma in situ
ASGS: Australian Statistical Geography Standard
C4: the NHMRC Centre of Research Excellence in Cervical Cancer Control
CIN: cervical intra epithelial neoplasia
Compass: the Compass trial, a randomised trial of over 76,000 women comparing HPV vs cytology based screening in Australia
HGA: High-grade abnormality
HPV: human papillomavirus
HSIL: high grade squamous intraepithelial lesion
IRSD: Index of Relative Socio-economic Disadvantage
MBS/PBS: Medicare Benefits Schedule/Pharmaceutical Benefits Scheme
MDT: Multi-disciplinary team
NCSP: National Cervical Screening Program
NCSR: National Cancer Screening Register
NCIRS: National Centre for Immunisation Research and Surveillance
NGOR: National Gynae-Oncology Register
NHMRC: National Health and Medical Research Council
OR: odds ratio
PLIDA: Person Level Integrated Data Asset
SA: Statistical Area
SEIFA: Socio-Economic Indexes for Areas
SES: Socio-economic status
WHO: World Health Organization
Standard abbreviations for Australia’s eight States and Territories: NSW, Vic, Qld, NT, SA, WA, Tas, ACT
Please note throughout this report we generally use the term ‘women’ to refer to people eligible for or attending cervical screening or experiencing cervical cancer. However, we respectfully acknowledge that some people with a cervix do not identify as women and are equally impacted by the risk of cervical cancer. Currently only sex at birth can be reported in this report.
The terms female and male are used when they relate to data collected and coded as either female or male, e.g. ABS estimated resident populations. The terms girls, boys and adolescents are used when referring to the cohorts receiving HPV vaccination through to 15 years of age.
The term Indigenous is used in Figures and Tables and when referring to data collected to ascertain a person's 'Indigenous status'; otherwise, we use the term Aboriginal and Torres Strait Islander people.
Key findings and recommendations
Executive Summary
In this sixth report on Australia’s progress towards the elimination of cervical cancer as a public health problem, progress is evident towards elimination across most indicators, with cervical cancer incidence falling slightly to 6.0 per 100,000 in 2022 and colposcopy and precancer treatment rates improving, but persistent and inequitable declines in HPV vaccination demand urgent attention. In 2025, vaccine coverage with a dose of HPV vaccine in girls by age 15 fell below 80% (to 78.7%) for the first time since the program began in 2007. Coverage in boys also continued to decline (to 75.6%). Sustained vaccine coverage below 80% (currently 77.1%) is not sufficient to achieve the elimination of targeted HPV types in the longer term. In addition, screening participation has increased slightly but remains below expected rates, potentially putting elimination by 2035 at risk.
Status of elimination efforts for Aboriginal and Torres Strait Islander people
Both incidence (12 per 100,000 2018-2022) and mortality (4.2 per 100,000 2020-2024) from cervical cancer among Aboriginal and Torres Strait Islander people remain unacceptably high. Whilst very low HPV 16/18 detection in screening women 25-34 years show the large and equitable impacts of past HPV vaccination efforts, HPV vaccine coverage amongst Aboriginal and Torres Strait Islander adolescents has continued to disproportionately decline with coverage now at 69.6% (72.6% girls, 66.8% boys). Priority investment in Aboriginal and Torres Strait Islander led initiatives are urgently needed to address this ongoing challenge. Resolving the longstanding absence of Aboriginal and Torres Strait Islander cervical screening participation estimates should be a national priority, as this remains a major barrier to delivering the screening needed to achieve equitable cervical cancer elimination by 2035.
Progress on disease outcomes
Overall cancer incidence rates appear to be following the pattern anticipated as part of the program’s transition from cytology to HPV screening (Indicator 1). After a transient increase, as the more sensitive HPV screening test led to earlier detection of some cancers, incidence rates declined from 6.6 per 100,000 in 2020 to 6.0 per 100,000 in 2022. However, inequities persist. In 2018-2022, the incidence of cervical cancer incidence among Aboriginal and Torres Strait Islander women was 12.0 cases per 100,000 women. This represents an incidence rate of three times the elimination threshold: therefore, a 67% reduction is needed to achieve cervical cancer elimination. There is also a clear socioeconomic gradient, with women living in the most disadvantaged areas having a cervical cancer incidence of 7.8 cases per 100,000 women in 2018–2022, almost twice the elimination threshold.
After an initial increase following the introduction of HPV-based screening, cervical cancer incidence declined in 2022 among women aged 25–29, 30–34 and 35–39 years. These declines are likely driven by the combined impact of more sensitive HPV-based screening and the increasing contribution of HPV-vaccinated cohorts reaching the ages at which cervical cancer typically occurs. Cervical cancer remains extremely rare in women aged <25 years (0.3 cases per 100,000) consistent with the expected impact of HPV vaccination.
Cervical cancer mortality was 1.4 per 100,000 women in the period 2020-2024 (most recent data) (Indicator 2). Mortality increased with increasing level of socioeconomic disadvantage and was three times higher among Aboriginal and Torres Strait Islander women (4.2 per 100,000).
Across women screened at all ages, biopsy confirmed pre-cancer (HSIL/ AIS) detection rates have also declined, by 21%, most likely reflecting a lower detection of disease among participants returning for their second round of HPV-based screening (Indicator 3). Lower rates are expected, as most prevalent disease was detected and treated in the first round (age-standardised rate per 1,000 women screened was 7.5 in 2024, compared to 9.6 in 2019, the corresponding year in the first round of HPV screening).
HPV prevalence remained low in 2025 (Indicator 4). HPV16/18 prevalence was just 1.6% nationally and 0.9% and 1.0% among women aged 25-29 and 30-34 years respectively, reflecting the sustained success of Australia's HPV vaccination program. This is the first time that HPV16/18 prevalence has ever been below 1% in screening women aged 25-29 years. Similarly low prevalence was observed among Aboriginal and Torres Strait Islander women aged 25-29 years (0.9%) and 30-34 years (0.8%). Non-16/18 oncogenic HPV types remain most common among younger women, although further reductions are expected as cohorts offered the nonavalent HPV vaccine begin reaching screening age from around 2030.
Vaccine coverage continues to decrease
Whilst the impact of previously high HPV vaccination rates across a large cohort of Australian girls and women are being seen across HPV infection and disease outcomes, HPV vaccine coverage by age 15 has continued to decline, from its peak of 85.7% in 2020 (86.6% in girls, 84.9% in boys) to 77.1% in 2025 (78.7% in girls; 75.6% in boys) (Indicator 5). This is the first time coverage with one or more doses of HPV vaccine has been below 80% in girls since the program commenced in 2007. Inequity in coverage remains marked among Aboriginal and Torres Strait Islander adolescents, by area, socioeconomic status and by jurisdiction of residence. These declines are likely multifactorial and relate to ongoing challenges in delivering school-immunisation programs in the current environment, with competing priorities for schools, students and parents, significant absenteeism, challenges in electronic communication and consent processes, and in the context of declines in vaccine confidence and coverage across the vaccine schedule both locally and globally.
It is now urgent that coordinated, funded national action is taken under the National Immunisation Strategy 2025-2030 to address these ongoing vaccine coverage declines. Redesigning current approaches to implement a fit for purpose adolescent centred immunisation system in 2026 requires not only commitment from every State health and education department but also the involvement of adolescents, young people, parents and priority population groups including Aboriginal and Torres Strait Islander people, people with disability, LGBTQ+ and people with variations in sex characteristics, people of migrant and refugee background and people experiencing socioeconomic disadvantage.
Screening coverage
The proportion of women aged 35-39 years who have had at least one HPV test in their lifetime continues to increase (Indicator 6). This proportion is now 88.1% nationally, exceeds 80% in all areas, and exceeds or is approaching 90% in many areas. Being screened at least once in a lifetime substantially reduces an individual’s cervical cancer risk, so this finding indicates a need to focus on the 12% of the population in this age window who have never had an HPV test. The proportion of screen-eligible people aged 45-49 years with at least two tests is also increasing over time and has reached 14.4% nationally. Some areas, where the proportion with at least one HPV test by 35-39 years has been increasing relatively more quickly, are progressing more slowly on the measure for a second HPV test (remote areas and the most disadvantaged areas). This suggests that self-collection is improving access for a first HPV test, but sustained efforts are needed to ensure that underserved populations receive regular screening.
Both measures of screening participation in line with Australia’s 5-yearly program have improved since last year (75.5% up to date with screening, 80.9% screened between 2021 – mid-2026), although the participation achieved prior to the declines seen over the previous two years has not yet been reached (Indicator 7A, Indicator 7B). Some groups have defied the recent declining trend: screening participation continued to increase through the last two periods in all age groups between 65 and 74, and in Tas. All of these groups have higher than average self-collection uptake. Self-collection appears to be continuing to improve equity by improving the relative performance in remote areas, Tasmania and the NT in particular. The interim Australian target of 70% 5 yearly screening participation has been met using the up-to-date measure (Indicator 7A) in all groups except for those aged 25-29 yrs (50.6%), 30-34 years (68.3%) and those resident in areas in the most disadvantaged quintile areas; and has been met using the AIHW measure (Indicator 7B) in all groups except those aged 70-74 years (67.3%). However, the proportion screening on time remained lower than model assumptions used to estimate when cervical cancer elimination would be achieved in Australia, and the findings for those aged 25-29 years continue to strongly suggest that screening initiation at age 25 remains low. Given that screening participation is a strong determinant of the timing of elimination, these consistent findings put the timing of cervical cancer elimination in Australia at risk. There is a need to overcome the remaining access and acceptability barriers for those people who are yet to engage or re-engage in screening despite the widespread availability of self-collection. Structural barriers such as out-of-pocket fees to access primary care and a shortage of availability of providers and appointments in many areas may be exacerbating reluctance to screen. Alternative models for people who need them such as telehealth, mail out, community outreach and pharmacy pick up models should be piloted and evaluated as complementary strategies.
Measures of treatment
There are ongoing issues with access to timely colposcopy, which could be due to access problems but also appear to be due to possible barriers to correctly identifying for referral those who should be classified as higher risk (Indicator 8). There are particular delays in the groups who are referred at a 12-month follow-up test if any HPV type is detected (exceptions to broader guidelines) due to either being overdue for screening or identifying as an Aboriginal or Torres Strait Islander person (39.8% and 43.4% seen within 12 months, respectively, compared to 81.4% nationally). Since the same delay is not seen for those who are exceptions due to being aged 50+, this likely reflects barriers to correctly identifying people as Aboriginal and Torres Strait Islander and/or overdue for screening, rather than lack of awareness or understanding of these exceptions among providers or colposcopy services. Systematic collection of Aboriginal and Torres Strait Islander status on all pathology forms would address one barrier. Laboratories also need information from the NCSR to enable them to identify individuals as overdue at their initial screen as we have been able to.
High-grade cervical disease treatment rates within 8 weeks, 6 months and 12 months generally increased slightly from 2023 to 2024: exceptions were for those residents in the lowest socioeconomic quintile areas, in inner regional areas and in the ACT (Indicator 9). The national treatment rate did not reach the 90% target for any timeframe (57.1% within 8 weeks, 85.3% within 6 months and 88.5% within 12 months) but was met at 12 months in remote areas (91.1%) and by half of the States and Territories (SA 90.3%, NT 91.1%, WA 92.2% and Tas 93.5%).
Although not yet nationally representative, with hospitals still being onboarded, data from the National Gynae-Oncology Registry for 467 people diagnosed with invasive cervical cancer in 2025 show that 94.0% received active cancer treatment. (Indicator 10). This is broadly consistent with registry data from 2024 and with rates estimated for all patients in Queensland 2015-2024. Two studies published in 2026 analysing data from patients with cervical cancer receiving radiotherapy in NSW and Queensland demonstrated that optimal care pathway targets for timeliness in treatment were often not met.
Cancer survival improved in 2018-2022 compared to the previous period (5-year relative survival 77.0%, compared with 73.9% in 2013-2017) (Indicator 11). Data shows an ongoing disparity for Aboriginal and Torres Strait Islander women in overall survival (5-year observed survival of 65.3% compared with 74.8% among non-Indigenous women). Relative survival by Aboriginal and Torres Strait Islander status is not available, and the overall lack of stage at diagnosis data limits understanding of survival differences and inequities.
Ongoing data challenges
We note that data remain unavailable to fully assess progress towards elimination for Aboriginal and Torres Strait Islander women, as well as other priority groups. Encouragingly, recent improvements in linked data infrastructure, including PLIDA and the National Health Data Hub, are creating new opportunities to generate more granular and complete data on screening participation, cervical cancer outcomes, and inequities among priority populations.
Encouragingly a slight improvement was noted in the underlying completeness of Aboriginal and Torres Strait Islander status data sourced from the National Cancer Screening Register for indicators used in this report compared to previous periods: however, completeness is still insufficient to enable screening participation rates to be estimated for Aboriginal and Torres Strait Islander people. This is because reporting is not mandatory i.e. it is not a required field on pathology forms when tests are collected from participants. Given the critical role of screening in meeting the 2035 elimination target, this is a very serious barrier to timely and equitable elimination. AIHW is undertaking a data linkage project on behalf of the Australian Government Department of Health, Disability and Ageing to improve reporting for Aboriginal and Torres Strait Islander people participating in the NCSP.
Cancer incidence data remains significantly lagged and reporting by Stage remains unavailable. We await the outcomes of the work currently underway to expedite reporting of cervical cancer cases from State and Territory cancer registries as part of the National Cervical Cancer Elimination Strategy.
Below is a table showcasing Australia's progress towards the elimination of cervical cancer against WHO targets.
Australia's progress towards the elimination of cervical cancer against WHO targets
Cervical cancer incidence |
Fewer than 4 new cases per 100,000 women |
6.0 new cases per 100,000 women in 2022, a modest decrease from 6.3 per 100,000 in 2021. Compared to the elimination target, rates were three times as high for Aboriginal and Torres Strait Islander women and twice as high in remote and very remote areas. |
HPV vaccine coverage by 2030 |
90% of girls vaccinated by the age of 15 years |
78.7%% in 2025, reduced from 2024 cohort by 2.4%. Inequity in coverage continues across available demographic variables, notably for Aboriginal and Torres Strait Islander adolescents and by jurisdiction of residence. |
Screening participation by 2030 |
70% of women screened using a high-performance test by age 35 years and again by age 45 years |
By the end of 2025, 88.1% of women aged 35-39 had been screened at least once with an HPV test Uptake of at least one test has particularly increased in remote and very remote areas, the NT, and more disadvantaged areas. Completion of at least 2 tests has increased most in the least disadvantaged areas; major cities and very remote areas; and the ACT and NT. |
Treatment of cervical precancer by 2030 |
90% of women with identified precancer are treated |
85.3% and 88.5% of those with cervical precancer detected in 2024 were treated within 6 and 12 months, respectively. The proportions treated have generally improved compared to those with high-grade cervical disease detected in 2023. |
Treatment of cervical cancer by 2030 |
Management of 90% of women with invasive cervical cancer |
No complete national data are available. Among 467 cervical cancer cases diagnosed in 2025 and reported to the National Gynae-Oncology Registry, 94.0% received cancer treatment. |